发明名称 |
Methods and uses of TIE2 binding and/or activating agents |
摘要 |
The present disclosure provides methods and uses of Tie2 binding and/or activating agents. In particular, the present disclosure provides methods and uses for inhibiting the expansion of colony forming unit-granulocytes, reducing eosinophils and/or basophils, for treating allergic disease or response or eosinophil/basophil associated condition and for reducing inflammatory cytokine and/or chemokine levels. |
申请公布号 |
US9186390(B2) |
申请公布日期 |
2015.11.17 |
申请号 |
US201113643171 |
申请日期 |
2011.04.28 |
申请人 |
Sunnybrook Health Sciences Center |
发明人 |
Van Slyke Paul;Dumont Daniel |
分类号 |
A61K38/08;A61K38/16;A61K38/17;A61K47/48;C07K7/04;C07K7/06;C07K14/475;C07K14/515;A61K38/18;A61K38/39;A01K67/027;A61K48/00 |
主分类号 |
A61K38/08 |
代理机构 |
Bereskin & Parr LLP |
代理人 |
Bereskin & Parr LLP ;Szweras Melanie |
主权项 |
1. A method for reducing eosinophils and/or basophils in an animal in need thereof comprising administering a multimeric form of Tie2 binding peptide monomers to the animal in need thereof, wherein the multimeric form has Tie2 agonist activity, wherein each peptide monomer comprises:
(i) a T7 peptide (SEQ ID NO:1) or a T7 modified peptide (SEQ ID NO:2); (ii) a GA3 peptide (SEQ ID NO:3) or a GA3 modified peptide (SEQ ID NO:4); (iii) a T4 peptide (SEQ ID NO:9) or a T4 modified peptide (SEQ ID NO:10); (iv) a T6 peptide (SEQ ID NO:7) or a T6 modified peptide (SEQ ID NO:8); or (v) a T8 peptide (SEQ ID NO:5) or a T8 modified peptide (SEQ ID NO:6); and wherein the Tie2 binding peptide monomers are multimerized via a linking moiety, spacer and/or multimerizing agent. |
地址 |
Toronto CA |